Prostate cancer-associated SPOP mutants display impaired binding to BET proteins, leading to reduced proteasomal degradation and accumulation of the protein in prostate cancer cell lines and patient specimens, and causing resistance to BET inhibitors (282). Here, SPOP is linked to prostate carcinoma.